Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 08:35 CEST (UTC+2h)

Topical Drugs- IVRT [Regulatives / Guidelines]

posted by MaggieSantos - Portugal, 2018-07-03 18:41  - Posting: # 19015
Views: 189

Hello,

Regarding the new draft guidance on acyclovir ointment I have performed an IVRT test to compare the test and reference formulations. I used a Hanson system similar to the ones used for acyclovir creams.

During the validation of the test system, I applied the described parameters on draft guidance for acyclovir cream, namely, IVRT Discrimination Sensitivity, Specificity and Selectivity.

When comparing the lower (2.5%) and upper (7.5%) release rates to the 5% acyclovir ointment (PEG basis), the release rates were nor discriminatory.

As anyone performed this test, what results were obtained and what is the suggested reason for no discriminatory results. What is the impact?:confused:

Kind Regards

MeggieSantos

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,192 registered users;
online 9 (0 registered, 9 guests [including 7 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed